The Orphan Drug Designation (ODD) is a status assigned by EMA to a medicine intended for use against a rare condition. The medicine must fulfil certain criteria for designation as an orphan medicine so that it can benefit from incentives such as protection from competition once on the market.
We have summarized the work process for you to have always at hand.
Have a look at the complete process:
For further information, queries or assistance, contact us at: [email protected]
Search News & Events
Share
The MHRA has issued a new guidance on the implementation of the Windsor Framework. This new guidance introduces revised definitions of authorisation types, for new
Preparing and submitting an Investigational Medicinal Product Dossier (IMPD) is a crucial step in the drug development process. At Asphalion, we offer reliable and comprehensive
Celebrating a Milestone in Medical Nanotechnology!
Services
Memberships & Partnerships
Quality Management System
© Asphalion
Schedule here a free 30-minutes meeting with one of our consultants and tell us about your project, challenges or doubts.
We will be happy to assist you!
